Seattle BioMed, AttoDx, Inc., and the University of Washington Announce Exclusive Technology License Agreement

Mon, 03/08/2010

Seattle, Washington. March 5, 2010—AttoDx, Inc. has signed an exclusive license agreement for molecular viabilitiy testing technology developed at the University of Washington and Seattle BioMed.  The licensed technology was developed by Dr. Gerard Cangelosi and Mr. Kris Weigel of Seattle BioMed, and Dr. Scott Meschke of the University of Washington, Department of Environmental Health.

AttoDx expects this technology to be a key element in the development of rapid pathogen detection products for use in medicine, food and water safety, and the environment.  The technology is highly sensitive and offers the unique ability to rapidly distinguish between living and dead pathogens.  AttoDx is a new company located in Seattle, Washington, focused on developing and commercializing pathogen detection and lab-on-a-chip products.  For more information, contact James Davie, CEO, AttoDx, Inc.,

Seattle BioMed is the largest independent, non-profit organization in the U.S. focused solely on infectious disease research.  Their research is the foundation for new drugs, vaccines and diagnostics.  By partnering with key collaborators around the globe, they ensure that their discoveries will save lives sooner.  For more information, visit or contact: Lee Schoentrup, Communications Director, Seattle BioMed.

University of Washington, School of Public Health, Department of Environmental and Occupational Health Sciences is a dynamic department focused on discovering and analyzing the links between human health and the environment.  The faculty is multidisciplinary and includes physicians, engineers, chemists, toxicologists, industrial hygienists, and other public health scientists.  For more information, visit:

James Davie, CEO
AttoDx, Inc.